Vanda Strikes Out at the Supreme Court
April 22, 2024, 3:57 PM
Two weeks ago we discussed Vanda Pharmaceuticals’ ambitious cert petition asking the Supreme Court to discontinue the “reasonable expectation of success” standard for patent obviousness that for decades has been a mainstay of patent law.
Vanda argued that the Court should instead adopt a “predictable results” standard, which would have made patents more difficult to challenge and thereby significantly impacted the pharma and biologics industries. Unsurprisingly, the Court today denied Vanda’s petition, leaving the obviousness standard unchanged.
To subscribe to our publications, click here.
Tags
News & Insights
News & Insights
American Bar Association 2025 Asia-Pacific Conference
Speaking Engagement
Antitrust
NBA Commercial Law Section 38th Annual Corporate Counsel Conference
Sponsorship
Antitrust
GCR Live: Law Leaders Global 2025
Speaking Engagement
Antitrust
SABA North America Corporate Counsel Retreat 2025
Sponsorship
Antitrust
Forecasting Health Care Antitrust Under a Second Trump Administration
Podcast
Antitrust
GCR 100 2025 Ranks Axinn Antitrust Group in Top Categories
Awards & Recognitions
Antitrust
What Trump’s FTC Picks Mean for Bio-Pharma Dealmaking and PBMs
Media Mentions
Antitrust
Capitol Forum Health Care Competition Conference 2024
Speaking Engagement
Antitrust
Ethical Considerations for Cybersecurity, IP Transactions and Avoiding USPTO Sanctions (EIP241212)
Speaking Engagement
Intellectual Property
Albertsons Ends Merger Deal, Accuses Kroger of ‘Self-Serving Conduct’
Media Mentions
Antitrust